nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

11.01.2018 | Original Article

The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma

verfasst von: Rosa Nguyen, Jim Houston, Wing K. Chan, David Finkelstein, Michael A. Dyer

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Although anti-disialoganglioside (GD2) antibodies are successfully used for neuroblastoma therapy, a third of patients with neuroblastoma experience treatment failure or serious toxicity. Various strategies have been employed in the clinic to improve antibody-dependent cell-mediated cytotoxicity (ADCC), such as the addition of interleukin (IL)-2 to enhance natural killer (NK) cell function, adoptive transfer of allogeneic NK cells to exploit immune surveillance, and retinoid-induced differentiation therapy. Nevertheless, these mechanisms are not fully understood. We developed a quantitative assay to test ADCC induced by the anti-GD2 antibody Hu14.18K322A in nine neuroblastoma cell lines and dissociated cells from orthotopic patient-derived xenografts (O-PDXs) in culture. IL-2 improved ADCC against neuroblastoma cells, and differentiation with all-trans retinoic acid stabilized GD2 expression on tumor cells and enhanced ADCC as well. Degranulation was highest in licensed NK cells that expressed CD158b (P < 0.001) and harbored a killer-cell immunoglobulin-like receptor (KIR) mismatch against the tumor-specific human leukocyte antigen (HLA; P = 0.016). In conclusion, IL-2 is an important component of immunotherapy because it can improve the cytolytic function of NK cells against neuroblastoma cells and could lower the antibody dose required for efficacy, thereby reducing toxicity. The effect of IL-2 may vary among individuals and a biomarker would be useful to predict ADCC following IL-2 activation. Sub-populations of NK cells may have different levels of activity dependent on their licensing status, KIR expression, and HLA–KIR interaction. Better understanding of HLA–KIR interactions and the molecular changes following retinoid-induced differentiation is necessary to delineate their role in ADCC.

Nur mit Berechtigung zugänglich

Zent CS, Chen JB, Kurten RC et al (2004) Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res 28:495–507. https://doi.org/10.1016/j.leukres.2003.09.011 CrossRefPubMed

Brentjens RJ, Davila ML, Riviere I et al (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5:177ra38. https://doi.org/10.1126/scitranslmed.3005930 CrossRefPubMedPubMedCentral

Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34. https://doi.org/10.1056/NEJMoa1504030 CrossRefPubMedPubMedCentral

Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792. https://doi.org/10.1056/NEJM200103153441101 CrossRefPubMed

Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342. https://doi.org/10.1056/NEJMoa032691 CrossRefPubMed

Yu AL, Gilman AL, Ozkaynak MF et al (2010) Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma. N Engl J Med 363:1324–1334. https://doi.org/10.1056/NEJMoa0911123 CrossRefPubMedPubMedCentral

Schulz G, Cheresh DA, Varki NM et al (1984) Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 44:5914–5920PubMed

Janeway CA Jr, Travers P, Walport M et al (2001) Immunobiology: The Immune System in Health and Disease. 5th edn. New York: Garland Science. The destruction of antibody-coated pathogens via Fc receptors. http://www.ncbi.nlm.nih.gov/books/NBK27171/. Accessed 6 May 2017

Kärre K, Ljunggren HG, Piontek G, Kiessling R (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319:675–678. https://doi.org/10.1038/319675a0 CrossRefPubMed

10.

Ruggeri L, Mancusi A, Capanni M et al (2007) Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110:433–440. https://doi.org/10.1182/blood-2006-07-038687 CrossRefPubMedPubMedCentral

11.

Henney CS, Kuribayashi K, Kern DE, Gillis S (1981) Interleukin-2 augments natural killer cell activity. Nature 291:335–338. https://doi.org/10.1038/291335a0 CrossRefPubMed

12.

Villablanca JG, Khan AA, Avramis VI et al (1995) Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 13:894–901. https://doi.org/10.1200/JCO.1995.13.4.894 CrossRefPubMed

13.

Stewart E, Shelat A, Bradley C et al (2015) Development and characterization of a human orthotopic neuroblastoma xenograft. Dev Biol 407:344–355. https://doi.org/10.1016/j.ydbio.2015.02.002 CrossRefPubMedPubMedCentral

14.

Downing JR, Wilson RK, Zhang J et al (2012) The pediatric cancer genome project. Nat Genet 44:619–622. https://doi.org/10.1038/ng.2287 CrossRefPubMedPubMedCentral

15.

Anders S, Pyl PT, Huber W (2015) HTSeq–a Python framework to work with high-throughput sequencing data. Bioinformatics 31:166–169. https://doi.org/10.1093/bioinformatics/btu638 CrossRefPubMed

16.

André P, Biassoni R, Colonna M et al (2001) New nomenclature for MHC receptors. Nat Immunol 2:661. https://doi.org/10.1038/90589 CrossRefPubMed

17.

Brunner KT, Mauel J, Cerottini JC, Chapuis B (1968) Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 14:181–196PubMedPubMedCentral

18.

Cederbrant K (2005) Natural killer cell assay. In: Vohr H-W (ed) Encyclopedic reference of immunotoxicology. Springer, Berlin, pp 469–472CrossRef

19.

Sorkin LS, Otto M, Baldwin WM et al (2010) Anti-GD2 with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain 149:135–142. https://doi.org/10.1016/j.pain.2010.01.024 CrossRefPubMedPubMedCentral

20.

Alderson KL, Luangrath M, Elsenheimer MM et al (2013) Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG. Cancer Immunol Immunother 62:665–675. https://doi.org/10.1007/s00262-012-1372-8 CrossRefPubMed

21.

Hank JA, Surfus J, Gan J et al (1994) Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother Emphas Tumor Immunol 15:29–37CrossRef

22.

Rossi AR, Pericle F, Rashleigh S et al (1994) Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood 83:1323–1328PubMed

23.

Brodin P, Lakshmikanth T, Johansson S et al (2009) The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. Blood 113:2434–2441. https://doi.org/10.1182/blood-2008-05-156836 CrossRefPubMed

24.

Joncker NT, Fernandez NC, Treiner E et al (2009) NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J Immunol 182:4572–4580. https://doi.org/10.4049/jimmunol.0803900 CrossRefPubMedPubMedCentral

25.

Howlander N, Noone A, Krapcho M et al (2011) SEER Cancer Statistics Review, 1975–2009. National Cancer Institute, Bethesda

26.

Navid F, Sondel PM, Barfield R et al (2014) Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol 32:1445–1452. https://doi.org/10.1200/JCO.2013.50.4423 CrossRefPubMedPubMedCentral

27.

Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823–1841CrossRefPubMed

28.

Hank JA, Robinson RR, Surfus J et al (1990) Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 50:5234–5239PubMed

29.

Ribeiro RC, Rill D, Roberson PK et al (1993) Continuous infusion of interleukin-2 in children with refractory malignancies. Cancer 72:623–628CrossRefPubMed

30.

Ladenstein R, Poetschger U, Gray J et al (2016) Toxicity and outcome of anti-GD2 antibody ch14.18/CHO in front-line, high-risk patients with neuroblastoma: final results of the phase III immunotherapy randomisation (HR-NBL1/SIOPEN trial). J Clin Oncol 34(15_suppl):Abstract 10500

31.

Atkins MB, Gould JA, Allegretta M et al (1986) Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. J Clin Oncol 4:1380–1391. https://doi.org/10.1200/JCO.1986.4.9.1380 CrossRefPubMed

32.

Lode H, Siebert N, Kietz S et al (2013) Long-term continuous infusion of anti-GD2 antibody CH14.18/CHO in relapsed/refractory neuroblastoma patients. J Immunother Cancer 1(1_suppl):Abstract P244CrossRef

33.

Delgado DC, Hank JA, Kolesar J et al (2010) Genotypes of NK Cell KIR Receptors, Their Ligands, and Fc Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy. Cancer Res 70:9554–9561. https://doi.org/10.1158/0008-5472.CAN-10-2211 CrossRefPubMedPubMedCentral

34.

Venstrom JM, Zheng J, Noor N et al (2009) KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res 15:7330–7334. https://doi.org/10.1158/1078-0432.CCR-09-1720 CrossRefPubMedPubMedCentral

35.

Marsh SGE, Parham P, Barber LD (2000) The HLA factsbook. Academic Press, San Diego

36.

Jin HJ, Nam HY, Bae YK et al (2010) GD2 expression is closely associated with neuronal differentiation of human umbilical cord blood-derived mesenchymal stem cells. Cell Mol Life Sci 67:1845–1858. https://doi.org/10.1007/s00018-010-0292-z CrossRefPubMed

37.

Zou Z, Nomura M, Takihara Y et al (1996) Isolation and characterization of retinoic acid-inducible cDNA clones in F9 cells: a novel cDNA family encodes cell surface proteins sharing partial homology with MHC class I molecules. J Biochem 119:319–328CrossRefPubMed

38.

Ho EL, Carayannopoulos LN, Poursine-Laurent J et al (2002) Costimulation of multiple NK cell activation receptors by NKG2D. J Immunol 169:3667–3675. https://doi.org/10.4049/jimmunol.169.7.3667 CrossRefPubMed

39.

Reynolds CP, Kane DJ, Einhorn PA et al (1991) Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res 366:203–211PubMed

40.

Schug TT, Berry DC, Shaw NS et al (2007) Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 129:723–733. https://doi.org/10.1016/j.cell.2007.02.050 CrossRefPubMedPubMedCentral

Titel: The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma
verfasst von: Rosa Nguyen
Jim Houston
Wing K. Chan
David Finkelstein
Michael A. Dyer
Publikationsdatum: 11.01.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 4/2018
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-017-2108-6

Springer Medizin

The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Epstein–Barr virus strain heterogeneity impairs human T-cell immunity

IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients

Combined sublethal irradiation and agonist anti-CD40 enhance donor T cell accumulation and control of autochthonous murine pancreatic tumors

Human c-SRC kinase (CSK) overexpression makes T cells dummy

Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+ TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy

Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies—the German Cancer Consortium approach

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie